The Omni Legend PET/CT will be only the sixth of its kind in British Columbia, highlighting Initio Medical Group’s dedication to driving advancements in nuclear medicine and theranostics. Nuclear medicine is a highly specialized field that uses small amounts of radioactive substances to diagnose and treat diseases, particularly cancer. This innovative technology ensures greater precision in tumor detection and targeting, playing a crucial role in cancer treatment.
Theranostics, an innovative approach combining therapy and diagnostics, is poised to revolutionize personalized cancer care. This method leverages molecular imaging and targeted treatments to tailor therapy plans to individual patient needs, with the goal of enhancing treatment efficacy while minimizing side effects. Such advancements have the potential to improve the quality of life for patients navigating the daunting cancer landscape.
“As we move forward, it is crucial to remember that cancer affects us all,” remarked Mina Bechai, CEO at Initio Medical Group. “By investing in nuclear medicine and theranostics, we invest in brighter futures for countless individuals and families touched by this disease.”
In Canada, access to advanced cancer treatments is limited, with effective therapies often out of reach for many patients who frequently turn to costly alternatives abroad. Currently, Canada ranks 24th out of 32 OECD countries in the number of PET scanners per capita5. Initio Medical Group aims to change this narrative by working alongside provincial authorities to expand healthcare infrastructure, ensuring cutting-edge diagnostics and treatment options are available to all, regardless of financial situation. The installation of the Omni Legend PET/CT scanner is a step towards bridging this gap, helping to support the possibility of improved outcomes for cancer patients with access.
“We are proud to see our technology used to improve the experience of clinicians and patients at Initio Medical Group,” said Mike Hamilton, President, GE HealthCare Canada. “With more than 30 years of experience in PET, we remain dedicated to pushing the boundaries of what is possible with molecular imaging, so clinicians have the tools and quantitative data they need to make more confident and accurate diagnoses for their patients in British Columbia.”
